Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli.

Ole De Backer; Arif A Khokhar; Gintautas Bieliauskas; Azeem Latib; Rishi Puri; Tamaz Shaburishvili; Maia Zhividze; Teona Zirakashvili; Anita Asgar; Amar Krishnaswamy; Santiago A Garcia; Rebecca T Hahn; Paul D. Mahoney; Thomas Waggoner; Gorav Ailawadi; Stanley Chetcuti; Won-Keun Kim; João Cavalcante; Kari Feldt; Jeffrey J. Popma; Augustin Coisne; David Meier; Christopher U. Meduri; Stephan Windecker; Michael J. Reardon; Vinayak N Bapat

doi:10.4244/eij-d-25-01106

Key Points

The research aims to assess the early outcomes of a new heart valve in specific patients.
Evaluated the DurAVR THV in patients with small aortic annuli
Measured clinical and echocardiographic outcomes after 30 days
The DurAVR THV showed promising clinical outcomes at 30 days
Encouraging echocardiographic results were also observed

Implication

Clinical outcomes were promising with the DurAVR valve in patients with small aortic annuli, suggesting further investigation is warranted.

Abstract

In patients with SAA, the DurAVR THV demonstrated promising clinical and echocardiographic outcomes at 30 days. Longer-term follow-up in larger cohorts is needed to confirm these encouraging early results.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Backer et al. (2025) studied this question.

synapsesocial.com/papers/6925198ec0ce034ddc35348a https://doi.org/10.4244/eij-d-25-01106

View Full Paper

Ask AI

Bookmark

Share

Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli.

Key Points

Implication

Abstract

Discussion

Cite This Study

Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading